Tagged with EUROPE

Oncology Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that it believes would drastically improve cancer mortality rates and quality of life for oncology patients.   Recent statistics show that…

Europe Christoph Stoller, the recently appointed president of Medicines for Europe, outlines the mission of his presidency, how the association and its members are working to tackle the issue of drug shortages across the continent, and the crucial importance of establishing a high-level dialogue between industry and governments. Adrian van den…

Facts Spain’s medtech imports have nearly doubled compared to its exports over the last four years. Overall the market has experienced steady growth. Made with Visme Infographic Maker   Germany may be Europe’s biggest medical technology manufacturer, but Spain comes in fifth with 6% of the total market. Made with Visme…

Europe Dentons Germany’s Peter Homberg outlines the key requirements that companies need to fulfil in order to import medical cannabis into Germany and how attitudes and legislation on the topic are shifting across Europe.   In order to import medicinal cannabis from another country to Germany, like many other countries, the…

Europe Janssen’s EMEA market access head Martin Price outlines the regulatory changes that need to be made for patients across Europe to better access cutting-edge cancer medicines.   Recent advances in medical science are the driving force behind the research and successful development of innovative cancer treatments in Europe. By targeting…

Opinion Veeva Systems Europe’s Paul Attridge highlights how a switch to a continuous model for regulatory operations could allow biopharmaceutical companies to submit high-quality regulatory submissions for their products faster than ever before.   Like continuous manufacturing, which is widely employed in other industries and is starting to show signs of…

Janssen PharmaBoardroom recently sat down with Janssen EMEA head Kris Sterkens, who outlined the enduring importance of Europe to the global group, even with the emergence of Asian power markets such as China and the continuing significance of the USA. Read the full interview here.   Where Europe really does excel…

Europe European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and fend off their inherent vulnerabilities according to a new report from specialist pharma and biotech consultancy Novasecta.   Focus 75…

Opinion Aditya Bhattacharji takes a look at the potentially damaging impact of political uncertainty across Europe – including the impending exit of the UK from the European Union – on pharmaceutical firms across the continent.   The right-leaning parties that will play a more prominent role in European politics are even…

Europe The European MidPharma Performance Ranking 2019 is taken from The Novasecta European Midpharma Report 2019, which examines how European mid-cap pharma companies are surviving and thriving. With scores assigned to R&D investment, commercial revenues and business development, this is a comprehensive list of the recent performance of some of Europe’s…

Europe From her vantage point as associate vice president for MSD’s Central & Eastern Europe (CEE) cluster, Gabriele Grom outlines the disparity that still exists in terms of access to cancer treatments across Europe and what must be done to bridge this gap.   Despite the existence of innovative treatments, cancer…

Europe Bringing together insights from the heads of some of Europe’s most prominent mid-cap pharma firms. The leaders of Ipsen, Genmab, Pierre Fabre, Esteve and Servier outline the strategic directions in which their companies are turning and how they are planning to ensure a successful future.   David Meek, Ipsen David…